Latest Healthcare News

PainChek’s UK pilot reveals significant clinical improvements and economic benefits, positioning the digital pain assessment app for broader adoption in Scotland and beyond.

Visionflex Group’s cornerstone investors are converting $3.25 million of debt into equity at double the last closing price, paving the way for a debt-free balance sheet and a streamlined capital structure.

Nyrada Inc. has released compelling preclinical data showing its drug candidate Xolatryp protects mitochondrial function by reducing calcium overload in brain injury models, bolstering confidence ahead of its Phase IIa trial in acute myocardial infarction.

Regis Healthcare acknowledges the Australian Government’s recent announcement to increase aged care funding through higher AN-ACC prices and hotelling supplements, aimed at supporting wage rises for care workers. The company is currently assessing the financial implications of these changes.

Orthocell’s nerve repair device Remplir is being adopted in Australia for nerve-sparing prostate cancer surgeries, aiming to reduce erectile dysfunction and urinary incontinence post-operation. This development could significantly expand Remplir’s market reach globally.

Race Oncology has uncovered that its anticancer drug bisantrene exists as three light-sensitive isomers, with only one showing potent activity. The company has filed patents to protect this active form, potentially extending its intellectual property rights until 2045.

Next Science has finalised the sale of nearly all its assets to OSARTIS GmbH for US$50 million, with plans to return approximately US$30 million net proceeds to shareholders following legal and tax review.

CSL Limited has partnered with Dutch biotech VarmX to develop VMX-C001, a novel treatment aimed at reversing bleeding in patients on FXa inhibitors, with FDA Fast Track status and a potential 2029 launch.

Oceania Healthcare has unveiled a comprehensive strategy focused on sales performance, operational excellence, and capital management to strengthen its aged care and retirement living portfolio. The company aims to reduce debt, enhance resident choice, and expand services while maintaining strong occupancy and shareholder returns.

Adherium Limited’s iCARE study reports unprecedented medication adherence improvements and sustained patient engagement in COPD and asthma care, highlighting significant clinical and economic benefits.

Artrya Limited has completed the first tranche of its A$75 million placement, raising approximately A$60 million to advance its AI-driven coronary artery disease platform. Eligible shareholders can now participate in a Share Purchase Plan at the same price.

Cleo Diagnostics has received encouraging feedback from the U.S. FDA on its ovarian cancer pre-surgical triage test, reinforcing its clinical trial design and regulatory strategy ahead of a critical 510(k) submission.